BioArctic and Eli Lilly Partner on Brain-Targeted Drug Delivery

Under the terms of the deal, BioArctic will utilize its BrainTransporter technology—which targets the transferrin receptor to shuttle medicine across the blood-brain barrier—to develop a new drug candidate alongside a molecule provided by Lilly. While BioArctic handles the initial development, Lilly assumes full authority over global commercialization and subsequent clinical progress. If the project hits specific development milestones, the total value of the agreement could climb to 800 million dollars, with BioArctic also securing tiered royalties on future product sales.

Gunilla Osswald, CEO of BioArctic, noted that the partnership reflects a growing industry interest in the firm's transport technology. This marks the fourth time the company has licensed the platform to external partners, though BioArctic maintains full rights to use the system for projects outside these specific agreements. The technology is designed to improve drug efficacy and dosing convenience for patients battling severe neurological conditions, an area where BioArctic has previously found success with its Alzheimer’s drug, Leqembi.